Paula Gratal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paula Gratal has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Raquel Largo
Joint and Bone Research Unit, Rheumatology Department, Jimenez Diaz Foundation University Hospital, Madrid, Spain
5 shared publications - Gabriel Herrero-Beaumont
Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Madrid, Spain
4 shared publications - Ana Lamuedra
Research Unit, Spanish Society of Rheumatology , Madrid
2 shared publications - Aránzazu Mediero
Joint and Bone Research Unit, Fundación Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz Universidad Autónoma de Madrid Madrid Spain
2 shared publications - Sandra Pérez-Baos
Bone and Joint Research Unit, Service of Rheumatology, IIS-Fundación Jiménez Díaz, Autonomous University of Madrid, Madrid, Spain
2 shared publications - Alfonso Gomez- Iturriaga
Department of Radiation Oncology, Cruces University Hospital, Biobizkaia Health Research Institute, Basque Country University (UPV/EHU), Bilbao, Spain
1 shared publication
Latest Publications
- 16 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Decade of Quality Oncology Practice Initiative in Spain: From Quality Measurement to Continuous Improvement in Oncology Practice
Purpose: We evaluated 10 years of Quality Oncology Practice Initiative (QOPI) implementation in Spain to characterize quality performance across successive stages of participation, assess sustainability over time, compare performance with contemporaneous QOPI benchmarks, identify persistent certification gaps, and examine quality performance across repeated certification and reassessment cycles. Methods: We conducted a longitudinal descriptive study of QOPI implementation in Spanish oncology practices between 2015 and 2025. Analyses included within-practice changes in QOPI quality measures among certified practices, comparing the last available precertification assessment with the first postcertification assessment, including disease-specific measures for breast, colorectal, and lung cancers, and descriptive comparisons between first participation and postcertification assessments, benchmarking against the contemporaneous QOPI aggregate, and findings from external certification and recertification surveys. Results: Within-practice longitudinal analyses among certified practices showed higher postcertification performance in several patient-centered measures, including emotional well-being assessment (75.56%-85.20%), infertility risk discussion (70.33%-78.67%), appropriate pain management (83.57%-89.15%), and pain assessment (83.56%-89.50%). Certified practices maintained broadly high performance over time, although lower postcertification performance was observed in some chemotherapy and other documentation measures. Benchmarking showed a shift: Pain assessment, emotional well-being assessment, appropriate pain management, and infertility counseling moved from below to above the contemporaneous QOPI aggregate after certification. External surveys identified recurrent opportunities for improvement in treatment verification and patient information and education. Conclusion: A decade of QOPI implementation in Spain was associated with sustained high-quality performance, higher scores in selected patient-centered measures after certification, and the identification of persistent opportunities for improvement. Repeated measurement, benchmarking, certification, and reassessment may support organizational change and continuous quality improvement.
- 16 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Decade of Quality Oncology Practice Initiative in Spain: From Quality Measurement to Continuous Improvement in Oncology Practice
Purpose: We evaluated 10 years of Quality Oncology Practice Initiative (QOPI) implementation in Spain to characterize quality performance across successive stages of participation, assess sustainability over time, compare performance with contemporaneous QOPI benchmarks, identify persistent certification gaps, and examine quality performance across repeated certification and reassessment cycles. Methods: We conducted a longitudinal descriptive study of QOPI implementation in Spanish oncology practices between 2015 and 2025. Analyses included within-practice changes in QOPI quality measures among certified practices, comparing the last available precertification assessment with the first postcertification assessment, including disease-specific measures for breast, colorectal, and lung cancers, and descriptive comparisons between first participation and postcertification assessments, benchmarking against the contemporaneous QOPI aggregate, and findings from external certification and recertification surveys. Results: Within-practice longitudinal analyses among certified practices showed higher postcertification performance in several patient-centered measures, including emotional well-being assessment (75.56%-85.20%), infertility risk discussion (70.33%-78.67%), appropriate pain management (83.57%-89.15%), and pain assessment (83.56%-89.50%). Certified practices maintained broadly high performance over time, although lower postcertification performance was observed in some chemotherapy and other documentation measures. Benchmarking showed a shift: Pain assessment, emotional well-being assessment, appropriate pain management, and infertility counseling moved from below to above the contemporaneous QOPI aggregate after certification. External surveys identified recurrent opportunities for improvement in treatment verification and patient information and education. Conclusion: A decade of QOPI implementation in Spain was associated with sustained high-quality performance, higher scores in selected patient-centered measures after certification, and the identification of persistent opportunities for improvement. Repeated measurement, benchmarking, certification, and reassessment may support organizational change and continuous quality improvement.
- 11 February 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (7) , 1639-1646
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
Purpose Genitourinary (GU) multidisciplinary tumour boards (GUMTBs) are key components of patient care, as they might lead to changes in treatment plan, improved survival, and increased adherence to guidelines. However, there are no guidelines on how GUMTBs should operate or how to assess their quality of performance. Methods A systematic literature review was conducted to identify criteria and indicators to evaluate quality in GUMTBs. A scientific committee—comprising 12 GU cancer specialists from seven disciplines—proposed a list of criteria and developed indicators, evaluated in two rounds of Delphi method. Appropriateness and utility of indicators were scored using a 9-point Likert scale. Consensus was defined as at least two-thirds of Delphi respondents selecting a score sub-category that encompassed the median score of the group. Results Forty-five criteria were selected to evaluate the quality of GUMTBs covering five dimensions: organisation, personnel, protocol and documentation, resources, and interaction with patients. Then, 33 indicators were developed and evaluated in the first round of Delphi, leading to a selection of 26 indicators in two dimensions: function, governance and resources, and GUMTB sessions. In the second round, consensus was reached on the appropriateness of all 26 indicators and on the utility of 24 of them. Index cards for criteria and indicators were developed to be used in clinical practice. Conclusions Criteria and indicators were developed to evaluate the quality of GUMTBs, aiming to serve as a guide to improve quality of care and health outcomes in patients with GU cancer.
- 11 February 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (7) , 1639-1646
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
Purpose Genitourinary (GU) multidisciplinary tumour boards (GUMTBs) are key components of patient care, as they might lead to changes in treatment plan, improved survival, and increased adherence to guidelines. However, there are no guidelines on how GUMTBs should operate or how to assess their quality of performance. Methods A systematic literature review was conducted to identify criteria and indicators to evaluate quality in GUMTBs. A scientific committee—comprising 12 GU cancer specialists from seven disciplines—proposed a list of criteria and developed indicators, evaluated in two rounds of Delphi method. Appropriateness and utility of indicators were scored using a 9-point Likert scale. Consensus was defined as at least two-thirds of Delphi respondents selecting a score sub-category that encompassed the median score of the group. Results Forty-five criteria were selected to evaluate the quality of GUMTBs covering five dimensions: organisation, personnel, protocol and documentation, resources, and interaction with patients. Then, 33 indicators were developed and evaluated in the first round of Delphi, leading to a selection of 26 indicators in two dimensions: function, governance and resources, and GUMTB sessions. In the second round, consensus was reached on the appropriateness of all 26 indicators and on the utility of 24 of them. Index cards for criteria and indicators were developed to be used in clinical practice. Conclusions Criteria and indicators were developed to evaluate the quality of GUMTBs, aiming to serve as a guide to improve quality of care and health outcomes in patients with GU cancer.
- Open Access
- 29 January 2019
- Published by Springer Nature in Journal of Inflammation
- Vol. 16 (1) , 2
Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis
In order to gain insight into the early effects drawn by JAK inhibitors on intra-joint JAK/STAT-dependent signaling, we sought synovial activation of STATs and their end-products, along with their modification with tofacitinib (TOFA), at flare-up in antigen induced arthritis (AIA). New Zealand rabbits were randomly assigned to four groups –healthy controls, AIA, TOFA-treated AIA, or TOFA-treated controls–. AIA was induced with 4 weekly intra-articular ovalbumin injections in sensitized animals. TOFA (10 mg·kg− 1·day− 1) was administered for the last 2 weeks. Animals were euthanized 24 h after the last injection. AIA animals showed high-grade synovitis, which was partially improved by TOFA. No effects of the treatment were found on serum C-reactive protein or on the synovial macrophage infiltration at this stage. Synovial MMP-1,-3 and -13 expression levels in treated AIA rabbits were found to drop to those of controls, while a downregulation of IL6, IFNγ and TNF was evident in treated versus untreated AIA rabbits. Concurrently, a reduction in pSTAT1 and SOCS1, but not in pSTAT3, SOCS3 or active NFκB-p65, was noted with TOFA. Studying the mechanism of action of immunomodulatory drugs represents a major challenge in vivo, since drug-dependent decreases in inflammation very likely mask direct effects on disease mechanisms. This study design allowed us to prevent any confounding effect resulting from reductions in the overall inflammatory status, hence assessing the true pharmacological actions of TOFA in a very severe synovitis. Our findings point to pSTAT1 and MMPs as early molecular readouts of response to this JAK inhibitor.
- 29 January 2019
- Published by Springer Nature in Journal of Inflammation
- Vol. 16 (1) , 2
Open AccessInhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis
In order to gain insight into the early effects drawn by JAK inhibitors on intra-joint JAK/STAT-dependent signaling, we sought synovial activation of STATs and their end-products, along with their modification with tofacitinib (TOFA), at flare-up in antigen induced arthritis (AIA). New Zealand rabbits were randomly assigned to four groups –healthy controls, AIA, TOFA-treated AIA, or TOFA-treated controls–. AIA was induced with 4 weekly intra-articular ovalbumin injections in sensitized animals. TOFA (10 mg·kg− 1·day− 1) was administered for the last 2 weeks. Animals were euthanized 24 h after the last injection. AIA animals showed high-grade synovitis, which was partially improved by TOFA. No effects of the treatment were found on serum C-reactive protein or on the synovial macrophage infiltration at this stage. Synovial MMP-1,-3 and -13 expression levels in treated AIA rabbits were found to drop to those of controls, while a downregulation of IL6, IFNγ and TNF was evident in treated versus untreated AIA rabbits. Concurrently, a reduction in pSTAT1 and SOCS1, but not in pSTAT3, SOCS3 or active NFκB-p65, was noted with TOFA. Studying the mechanism of action of immunomodulatory drugs represents a major challenge in vivo, since drug-dependent decreases in inflammation very likely mask direct effects on disease mechanisms. This study design allowed us to prevent any confounding effect resulting from reductions in the overall inflammatory status, hence assessing the true pharmacological actions of TOFA in a very severe synovitis. Our findings point to pSTAT1 and MMPs as early molecular readouts of response to this JAK inhibitor.
- 1 April 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26, S73-S74
The ginger derivate 6-shogaol as a treatment in osteoarthritis. Modulation of chondrocyte hypertrophy and matrix calcification
- 1 April 2018
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 26, S73-S74
The ginger derivate 6-shogaol as a treatment in osteoarthritis. Modulation of chondrocyte hypertrophy and matrix calcification
- Open Access
- 24 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis
Inflammatory activity in rheumatoid arthritis may alter the regulation of muscle mass leading to a secondary sarcopenia, commonly termed rheumatoid cachexia (RC). We characterized alterations to muscle structure and various pro-inflammatory, catabolic and regenerative markers in an animal model of RC. Antigen induced arthritis (AiA) was performed in 20 male adult rabbits. AiA animals exhibited significantly less weight gain, a markedly elevated serum C-reactive protein (CRP), lighter muscles with shorter cross-sectional diameter and increased myonuclei when compared to controls. Atrogin-1 and MuRF-1 were up-regulated alongside an increase in IL-1β, active NF-κB and a higher ratio of phosphorylated to inactive p38 MAPK. CCL-2 and TNF levels were reduced and IL-6 was unchanged between groups. We observed decreased pSTAT3, unchanged pSTAT1 and Myf5, but increased Pax7, MyoD and myogenin. AiA rabbits had a reduction in myostatin from gastrocnemii and synovium with a congruent decrease in serum myostatin compared to controls. Chronic arthritis induced an RC-like secondary sarcopenia with increased muscle protein breakdown. Elevated IL-1β may trigger proteolysis via elevated NF-κB and p38 MAPK signaling with a compensatory anabolic response suggested by myonuclear expansion, increased Pax7, MyoD and myogenin, reduced pSTAT3 as well as reduced serum, synovial and muscular myostatin.
- 24 July 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Open AccessCompensatory anabolic signaling in the sarcopenia of experimental chronic arthritis
Inflammatory activity in rheumatoid arthritis may alter the regulation of muscle mass leading to a secondary sarcopenia, commonly termed rheumatoid cachexia (RC). We characterized alterations to muscle structure and various pro-inflammatory, catabolic and regenerative markers in an animal model of RC. Antigen induced arthritis (AiA) was performed in 20 male adult rabbits. AiA animals exhibited significantly less weight gain, a markedly elevated serum C-reactive protein (CRP), lighter muscles with shorter cross-sectional diameter and increased myonuclei when compared to controls. Atrogin-1 and MuRF-1 were up-regulated alongside an increase in IL-1β, active NF-κB and a higher ratio of phosphorylated to inactive p38 MAPK. CCL-2 and TNF levels were reduced and IL-6 was unchanged between groups. We observed decreased pSTAT3, unchanged pSTAT1 and Myf5, but increased Pax7, MyoD and myogenin. AiA rabbits had a reduction in myostatin from gastrocnemii and synovium with a congruent decrease in serum myostatin compared to controls. Chronic arthritis induced an RC-like secondary sarcopenia with increased muscle protein breakdown. Elevated IL-1β may trigger proteolysis via elevated NF-κB and p38 MAPK signaling with a compensatory anabolic response suggested by myonuclear expansion, increased Pax7, MyoD and myogenin, reduced pSTAT3 as well as reduced serum, synovial and muscular myostatin.